Carolyn Enever

This inventor holds 15 USPTO granted patents and 11 published patent applications, plus 4 CIPO patents and 8 EPO patents, primarily in Protein Engineering. Top assignees: Glaxo Group Limited, Domantis Limited, Glaxosmithkline Intellectual Property Development Limited. Active years: 2013-2020.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Carolyn Enever. Retrieved from https://idiyas.com/inventor/carolyn-enever

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 15 (Patent Applications = 11)

% Patents Active = 60.0

CIPO Patents = 4 (Patent Applications = 2)

EPO Patents = 8 (Patent Applications = 21)

Average Co-Inventor Count = 4.5

ph-index = 3

Forward Citations = 18(Granted Patents)

Location History:

Cambridgeshire, GB (2013)
Stevenage, GB (2017)
Cambridge, GB (2013 - 2020)

Company Filing History:

Glaxosmithkline Intellectual Property Development Limited

patents

4. 1 out of 834,659

Other

patents

Years Active: 2013-2020

Loading Chart...

Areas of Expertise:

Anti-Serum Albumin

Polypeptides

Protease Resistant

Antibody Variable Domains

Antagonists

TNFR1

Binding Variants

Methods of Use

Selection Methods

Polypeptide Engineering

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10696738 - Anti-serum albumin binding variants (2020-06-30),

2. 10466252 - Methods for selecting protease resistant polypeptides (2019-11-05),

3. 10302655 - Methods for selecting protease resistant polypeptides (2019-05-28),

4. 10072089 - Polypeptides, antibody variable domains and antagonists (2018-09-11),

5. 9751935 - Anti-serum albumin binding variants (2017-09-05),

6. 9562090 - Polypeptides, antibody variable domains and antagonists (2017-02-07),

7. 9534043 - Anti-serum albumin binding variants (2017-01-03),

8. 9175071 - Anti-serum albumin binding variants (2015-11-03),

9. 9040668 - Anti-serum albumin binding variants (2015-05-26),

10. 9028822 - Antagonists against TNFR1 and methods of use therefor (2015-05-12),

11. 9012609 - Anti-serum albumin binding variants (2015-04-21),

12. 8877186 - Polypeptides, antibody variable domains and antagonists (2014-11-04),

13. 8685895 - Methods for selecting protease resistant polypeptides (2014-04-01),

14. 8398979 - Polypeptides, antibody variable domains and antagonists (2013-03-19),

15. 8357780 - Polypeptides, antibody variable domains and antagonists methods for (2013-01-22),

Title: The Innovative Contributions of Carolyn Enever

Introduction

Carolyn Enever is a prominent inventor based in Cambridge, GB. She has made significant contributions to the field of biotechnology, particularly in the development of therapeutic proteins. With a total of 15 patents to her name, Enever's work has had a substantial impact on medical science.

Latest Patents

Among her latest patents, Enever has developed improved variants of the anti-serum albumin immunoglobulin single variable domain DOM7h-11. This invention relates to ligands and drug conjugates that comprise such variants, as well as compositions, nucleic acids, vectors, and hosts. Another notable patent involves methods for selecting protease-resistant polypeptides. This disclosure outlines a method for isolating peptides or polypeptides that are resistant to degradation by proteases, which can be crucial for therapeutic applications in treating diseases in humans.

Career Highlights

Enever has worked with notable companies in the biotechnology sector, including Glaxo Group Limited and Domantis Limited. Her experience in these organizations has allowed her to refine her skills and contribute to groundbreaking research in her field.

Collaborations

Some of her notable coworkers include Ian M Tomlinson and Laurent S Jespers. Their collaborative efforts have further advanced the research and development of innovative therapeutic solutions.

Conclusion

Carolyn Enever's contributions to biotechnology through her patents and collaborations highlight her role as a leading inventor in the field. Her work continues to influence the development of new therapeutic strategies, showcasing the importance of innovation in medical science.

Profile summary based on public USPTO records.